Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.

The assessment of brain volume change with serial MRI provides an objective measure of an important component of the pathology of multiple sclerosis. Glatiramer acetate (GA) has a beneficial effect on clinical and MRI measures of disease activity and burden in patients with relapsing-remitting (RR) multiple sclerosis. This study investigated the impact of GA treatment on the development of brain atrophy in RR multiple sclerosis patients. The study consisted of a 9-month, double-blind, placebo-controlled phase followed by a 9-month open-label phase. Patients were randomized to receive either 20 mg GA or placebo by daily subcutaneous injections and underwent brain MRI scans every month during the first phase, and every 3 months during the second phase of the study. Using a semi-automated segmentation technique based on local thresholding, brain volume was measured from seven contiguous periventricular slices from the scans obtained at baseline, the end of the double-blind phase and the end of the study. From the original trial cohort, image sets from 113 out of 119 patients randomized to GA, and 114 out of 120 randomized to placebo treatment were evaluated. Brain volume was significantly correlated with patients' disability at each time-point. No significant differences between placebo- and GA-treated patients were found for baseline brain volume and rate of brain volume change over the study, even though a possible late trend for treatment with GA to retard the loss of brain volume was observed. There was a significant, but modest, correlation between MRI activity during the double-blind phase, and brain volume change over the entire study among patients originally treated with placebo. The modest correlation between enhancement frequency and brain atrophy loss indicates that the suppression of inflammatory activity in RR multiple sclerosis patients is not fully and rapidly associated with a similar effect on the global neurodegenerative processes. This study also suggests that any effect of GA in preventing brain volume decrease is not evident early following institution of treatment.

[1]  Ludwin Sk,et al.  The neuropathology of multiple sclerosis. , 2000 .

[2]  M. Horsfield,et al.  A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. , 1998, Brain : a journal of neurology.

[3]  F. Pfrieger,et al.  Synaptic efficacy enhanced by glial cells in vitro. , 1997, Science.

[4]  I. Allen,et al.  A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis , 1979, Journal of the Neurological Sciences.

[5]  Caterina Mainero,et al.  Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability , 2000, Journal of the Neurological Sciences.

[6]  M Rovaris,et al.  Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. , 1999, Current opinion in neurology.

[7]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[8]  Ponnada A Narayana,et al.  United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates , 2001 .

[9]  R. Rudick,et al.  Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability , 1999 .

[10]  L D Blumhardt,et al.  Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. , 1999, Brain : a journal of neurology.

[11]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[12]  J. Wolinsky,et al.  Linomide in relapsing and secondary progressive MS , 2000, Neurology.

[13]  Gianpaolo Donzelli,et al.  Catch-Up Growth in Short-at-Birth NICU Graduates , 2000, Hormone Research in Paediatrics.

[14]  J. Krieger,et al.  Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. , 2000, The Journal of clinical investigation.

[15]  C. Raine.  Comparative neuropathology and immunopathology of multiple sclerosis and HTLV-1 myelopathy , 1992, Journal of Neuroimmunology.

[16]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[17]  J S Wolinsky,et al.  Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability , 1998, Neurology.

[18]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[19]  Henry F. McFarland,et al.  Multiple sclerosis : clinical and pathogenetic basis , 1997 .

[20]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[21]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[22]  Marco Rovaris,et al.  Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis , 2000, Journal of Neurology.

[23]  F. Barkhof,et al.  Primary and transitional progressive MS , 1999, Neurology.

[24]  P. Dastidar,et al.  Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis , 1999, Journal of the Neurological Sciences.

[25]  A. Meshorer,et al.  Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Sormani,et al.  Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis , 1998, Neurology.

[27]  J K Udupa,et al.  Glatiramer acetate (Copaxone) treatment in relapsing–remitting MS , 2000, Neurology.

[28]  L D Blumhardt,et al.  Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.

[29]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[30]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[31]  R. Herndon,et al.  A longitudinal study of brain atrophy in relapsing multiple sclerosis , 1999, Neurology.

[32]  E. Waubant,et al.  A pilot study of MRI activity before and during interferon beta-1a therapy , 1999, Neurology.

[33]  M. Sela,et al.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Massimo Filippi,et al.  European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.

[35]  G J Barker,et al.  Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. , 1997, Brain : a journal of neurology.

[36]  G. Comi,et al.  Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium , 1998, Neurology.

[37]  M. Rovaris,et al.  Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients , 1999, Journal of the Neurological Sciences.

[38]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[39]  A. Compston,et al.  Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis , 1999, Annals of neurology.

[40]  H. Adams,et al.  Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.

[41]  G. Barker,et al.  Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H , 1999, Neurology.

[42]  I. Duncan,et al.  Induction of sodium channel clustering by oligodendrocytes , 1997, Nature.

[43]  J S Wolinsky,et al.  United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. , 2001, Multiple sclerosis.

[44]  W. Jagust,et al.  Brain atrophy as a surrogate marker in MS , 2000, Neurology.

[45]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[46]  G J Barker,et al.  The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.

[47]  M Rovaris,et al.  Whole brain volume changes in patients with progressive MS treated with cladribine , 2000, Neurology.

[48]  C. Farina,et al.  Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.